Given the broad applicability of its proprietary G-Technology® and the resulting multitude of options for internal development, 2-BBB strives to maximize the value of its development efforts for patients, partners and investors by applying a multidimensional and in-depth selection procedure to select promising programs. Focusing on compound-disease-combinations with a high unmet medical need for preclinical and clinical development only, 2-BBB has leveraged its G-Technology to develop two lead clinical programs targeting multiple indications of brain cancers and neuroinflammatory diseases.

2-BBB's lead product 2B3-101 (glutathione PEGylated liposomal doxorubicin, now 2X-111 and further developed by Oncology Venture's 2X Oncology) combines the G-Technology with the existing chemotherapeutic agent doxorubicin to enable treatment of brain metastases and glioma. It has completed a Phase I/IIa trial treating patients with various forms of brain cancer. In addition, a consortium of Dutch research groups have received a research grant to investigate the combination of 2B3-101 with focused ultrasound in pediatric brain tumors.   

Our second product, 2B3-201 (glutathione PEGylated liposomal methylprednisolone, now ENX-201 and further developed by EnhanX Biopharm Inc.), applies the anti-inflammatory glucocorticoid methylprednisolone to combat acute and chronic neuro-inflammation associated with several CNS indications including acute relapses of multiple sclerosis (MS), optic neuritis, neuromyelitis optica (NMO) and uveitis. 2B3-201 has completed a Phase I clinical trial in healthy volunteers.

LP-DF003 is developed by Mireca Medicines GmbH (Mireca), a Tübingen based pre-clinical stage bio-pharmaceutical company focusing on research and development of treatments for rare, neuro-degenerative eye diseases. Mireca was set up with the aim to translate research data generated in the EU-funded DRUGSFORD project into treatments for patients, with all original consortium partners as shareholders, while the translational science continues to be progressed in the EU-funded International Training Network transMed. Thus providing access to a network of experienced scientists and entrepreneurs, all relevant intellectual property and a GMP-compliant manufacturing process. The lead compound LP-DF003 is a small molecule capable of down regulating over expressed cGMP in inherited retina degeneration, covering a broad amount of underlying gene mutations. Mireca will first develop LP-DF003 for Retinitis Pigmentosa for which the EMA Orphan Drug Status (ODD) was granted and no other treatment option is currently available.